youtube_live
Q3 2026 daromadi • nashr etilgan • Aksiya boʻyicha daromad kutilganidan past -1,55%
Natijalarini ochishchevron_right
CMPS:NASDAQ
Compass Pathways PLC
7,81 US$
arrow_downward
-9,19%(-0,79) 1K
8,03 US$
arrow_upward
+2,82% (+0,22)todayBirjadan oldin
Savdolar yopilgan: 5-noy, 16:00:00 (GMT-5) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoCMPS tikeri uchun statistika yaratilmoqda...
Ochish
8,46 US$
Yuqori
8,61 US$
Past
7,78 US$
Bozor kapitali
1,11 mlrd
Oʻrtacha hajm
3,27 mln
Hajmi
1,98 ming
52 haftalik eng yuqori
15,87 US$
52 haftalik eng past
4,88 US$
Aksiya boʻyicha daromad
-2,10 US$
Beta
2,43
Muomaladagi aksiyalar
141,71 mln
Xodimlar soni
156
Ochish
8,46 US$
Yuqori
8,61 US$
Past
7,78 US$
Bozor kapitali
1,11 mlrd
Oʻrtacha hajm
3,27 mln
Hajmi
1,98 ming
52 haftalik eng yuqori
15,87 US$
52 haftalik eng past
4,88 US$
Aksiya boʻyicha daromad
-2,10 US$
Beta
2,43
Muomaladagi aksiyalar
141,71 mln
Xodimlar soni
156
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Stocks Down Under
·
17 soat oldin
Compass Pathways (NDQ:CMPS): Can Psychedelic Therapy Become Mainstream Medicine? If So, This Company Is Well Poised To Win!
Yahoo Finance
·
2 kun oldin
How Investors May Respond To COMPASS Pathways (CMPS) Smaller Loss And FDA Progress
Yahoo Finance
·
2 kun oldin
Compass Pathways Q3 Earnings Call Highlights
Yahoo Finance
·
3 kun oldin
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
Profil
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Wikipedia
Compass Pathways PLC haqida
CEO-
Xodimlar soni156
Asos solingan13-iyn, 2016
Bosh ofislar-
SektorHealth Care
Industry-
Veb-saytcompasspathways.com